Antisense Therapeutics Ltd: Change of Director's Interest Notice (CG,JG)
Antisense Therapeutics Ltd: Antisense completes Unmarketable Parcels facility
Antisense Therapeutics Ltd: Change of Director's Interest Notice (JG)
Antisense Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Antisense Therapeutics Ltd: Antisense to participate in upcoming investor conferences
Antisense Therapeutics Ltd: Change of Director's Interest Notice GP
Antisense Therapeutics Ltd: Publication of final Long COVID data for ATL1102
Antisense Therapeutics Ltd: Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
Antisense Therapeutics Ltd: Appendix 4G
Antisense Therapeutics Ltd: Corporate Governance Statement
Antisense Therapeutics Ltd: Change of Director's Interest Notice (CG,JG)
Antisense Therapeutics Ltd: Commencement of Chief Executive Officer
Antisense Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Antisense Therapeutics Ltd: Positive new DMD Combination Therapy Data in mdx mice
Antisense Therapeutics Ltd: Quarterly Activities Report
Antisense Therapeutics Ltd: Trading Halt
Antisense Therapeutics Ltd: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
Antisense Therapeutics Ltd: First Patient Dosed in ATL1102 Phase IIb DMD Trial
Antisense Therapeutics Ltd: Final Director's Interest Notice
Antisense Therapeutics Ltd: Change of Director's Interest Notice (JG)
No Data